These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

98 related articles for article (PubMed ID: 21910699)

  • 1. Long-term efficacy of etanercept for psoriasis in daily practice.
    Van Lümig PP; Driessen RJ; Boezeman JB; Van De Kerkhof PC; De Jong EM
    Br J Dermatol; 2012 Feb; 166(2):445-7. PubMed ID: 21910699
    [No Abstract]   [Full Text] [Related]  

  • 2. Three-year registry data on biological treatment for psoriasis: the influence of patient characteristics on treatment outcome.
    Driessen RJ; Boezeman JB; van de Kerkhof PC; de Jong EM
    Br J Dermatol; 2009 Mar; 160(3):670-5. PubMed ID: 19210502
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Etanercept: effectiveness and safety data of a retrospective study.
    Antoniou C; Vergou T; Dessinioti C; Stratigos AJ; Avgerinou G; Stavropoulos P; Katsambas A
    J Eur Acad Dermatol Venereol; 2011 Sep; 25(9):1113-5. PubMed ID: 20673305
    [No Abstract]   [Full Text] [Related]  

  • 4. Etanercept combined with methotrexate for high-need psoriasis.
    Driessen RJ; van de Kerkhof PC; de Jong EM
    Br J Dermatol; 2008 Aug; 159(2):460-3. PubMed ID: 18547310
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term management of erythrodermic psoriasis with anti-TNF agents.
    Romero-Maté A; García-Donoso C; Martinez-Morán C; Hernández-Núñez A; Borbujo J
    Dermatol Online J; 2010 Jun; 16(6):15. PubMed ID: 20579470
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effective control of psoriasis by etanercept in a patient with HCV-related diseases.
    Piccolo D; Di Cesare A; Fargnoli MC; Paoloni M; Vecchiotti S; Peris K
    Eur J Dermatol; 2008; 18(4):459-60. PubMed ID: 18573723
    [No Abstract]   [Full Text] [Related]  

  • 7. Combination of skin, joint and quality of life outcomes with etanercept in psoriasis and psoriatic arthritis in the PRESTA trial.
    Prinz JC; Fitzgerald O; Boggs RI; Foehl J; Robertson D; Pedersen R; Molta CT; Freundlich B
    J Eur Acad Dermatol Venereol; 2011 May; 25(5):559-64. PubMed ID: 20840349
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Etanercept does not have an apoptosis-inducing effect on psoriatic keratinocytes.
    Tatlican S; Arikok A; Gulbahar O; Eren C; Cevirgen B; Eskioglu F
    J Dermatolog Treat; 2010 Sep; 21(5):306-10. PubMed ID: 19878038
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Successful treatment of systemic cold contact urticaria with etanercept in a patient with psoriasis.
    Gualdi G; Monari P; Rossi MT; Crotti S; Calzavara-Pinton PG
    Br J Dermatol; 2012 Jun; 166(6):1373-4. PubMed ID: 22212112
    [No Abstract]   [Full Text] [Related]  

  • 10. Initial experience with routine administration of etanercept in psoriasis.
    de Groot M; Appelman M; Spuls PI; de Rie MA; Bos JD
    Br J Dermatol; 2006 Oct; 155(4):808-14. PubMed ID: 16965432
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Switching to adalimumab in patients with moderate to severe psoriasis who have failed on etanercept: a retrospective case cohort study.
    Woolf RT; Smith CH; Robertson K; Barker JN
    Br J Dermatol; 2010 Oct; 163(4):889-92. PubMed ID: 20854408
    [No Abstract]   [Full Text] [Related]  

  • 12. Patient-reported outcomes of psoriasis improvement with etanercept therapy: results of a randomized phase III trial.
    Krueger GG; Langley RG; Finlay AY; Griffiths CE; Woolley JM; Lalla D; Jahreis A
    Br J Dermatol; 2005 Dec; 153(6):1192-9. PubMed ID: 16307657
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Topical calcipotriene 0.005% and betamethasone dipropionate 0.064% maintains efficacy of etanercept after step-down dose in patients with moderate-to-severe plaque psoriasis: results of an open label trial.
    Kircik LH
    J Drugs Dermatol; 2011 Aug; 10(8):878-82. PubMed ID: 21818509
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Two years of experience with etanercept in recalcitrant psoriasis.
    Ahmad K; Rogers S
    Br J Dermatol; 2007 May; 156(5):1010-4. PubMed ID: 17408393
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Results of three analytical approaches on long-term efficacy of etanercept for psoriasis in daily practice.
    van Lümig PP; Driessen RJ; Kievit W; Boezeman JB; van de Kerkhof PC; de Jong EM
    J Am Acad Dermatol; 2013 Jan; 68(1):57-63. PubMed ID: 22846689
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of calcipotriol on etanercept partial responder psoriasis vulgaris and psoriatic arthritis patients.
    Campione E; Mazzotta A; Paternò EJ; Diluvio L; Prinz JC; Chimenti S
    Acta Derm Venereol; 2009; 89(3):288-91. PubMed ID: 19479128
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Etanercept therapy allows the tapering of methotrexate and sustained clinical responses in patients with moderate to severe psoriasis.
    Yamauchi PS; Lowe NJ
    Int J Dermatol; 2008 Feb; 47(2):202-4. PubMed ID: 18211500
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety and efficacy study on etanercept in patients with plaque psoriasis.
    Costanzo A; Mazzotta A; Papoutsaki M; Nisticò S; Chimenti S
    Br J Dermatol; 2005 Jan; 152(1):187-9. PubMed ID: 15656833
    [No Abstract]   [Full Text] [Related]  

  • 19. Patient-reported outcomes in pediatric patients with psoriasis undergoing etanercept treatment: 12-week results from a phase III randomized controlled trial.
    Langley RG; Paller AS; Hebert AA; Creamer K; Weng HH; Jahreis A; Globe D; Patel V; Orlow SJ
    J Am Acad Dermatol; 2011 Jan; 64(1):64-70. PubMed ID: 20619489
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and safety of etanercept in patients with psoriasis and hepatitis C.
    Ventura F; Gomes J; Duarte Mda L; Fernandes JC; Brito C
    Eur J Dermatol; 2010; 20(6):808-9. PubMed ID: 20923749
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.